According to the results of a large study conducted on over 17,000 people, the administration of semaglutide can reduce the risk of kidney disease and complications in people with obesity or overweight. But be careful not to mistake this drug for a do-it-yourself remedy: it can only be taken under medical prescription and in certain circumstances.
After the discovery of its potential beneficial effects for cardiovascular health, we are back to talking about semaglutitethe active ingredient initially used in the treatment of diabetes and then also proved to be effective in the treatment of obesity and overweight in certain circumstances which are exclusively up to the doctor to evaluate.
Now, semaglutide, also known by the name of one of the best-known drugs that contains it,Ozempicwould appear to have protective effects on the kidney health in people with obesity or overweight.
From the results of a large study conducted on more than 17,000 people in fact, it has emerged that the administration of this active ingredient can reduce the number of serious events related to kidney disease in a significant number of patients, also reducing the mortality rate.
Semaglutide, why it helps you lose weight and what the side effects are: “Pay attention to the indications”
What the study results suggest
The study in question is actually the same one that investigated cardiovascular health in obese or overweight people treated with semglutide, highlighting the ability of this drug to reduce heart attacks and strokes in these patient categories. Let’s talk about “SELECT” studio (Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity), of which the new results, relating to the effects of the drug on the kidneys, were released on the occasion of the 61st congress ofEuropean Renal Association (ERA)the European Kidney Health Association.
Three and a half years after the start of the study it emerged that the adverse events related to kidney health they were 22% less frequent in the patients they received a subcutaneous injection of 2.4 mg of semaglutide once a week compared to those reported in the comparison group who did not receive the drug. Among the adverse events are considered deathsignificant decline (greater than 50%) of renal function or development of persistent microalbumimuriaor the presence of quantities above the norm albumin in urine. The researchers highlighted the importance of this finding as this condition is considered among the main causes of kidney problems.
Semaglutide is not a do-it-yourself drug
Given that people with obesity are among the most predisposed to develop kidney complicationsAccording to the researchers, this study offers an encouraging perspective on the possible use of semaglutide in this category. In fact, the study – we reiterate – was conducted and refers to people with obesity or overweight.
Furthermore, there has been a lot of talk about semaglutide in recent months, especially after more and more people, including pfamous peoplestarted taking it to lose weight, even before the effectiveness and safety of this method of intake was confirmed by competent scientific authorities. However, as Professor Annalisa Capuano of the Italian Society of Pharmacology (SIF) explained to Fanpage.it, semaglutide remains a drug and as such it is not devoid of side effects: also for this reason it should only be taken below medical prescription and it cannot be treated like a common DIY remedy to lose a few pounds.
